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Background: The anterior cingulate cortex (ACC) is a brain area involved in modulating behavior associated with
social interaction, disruption of which is a core feature of autism spectrum disorder (ASD). Functional brain imaging
studies demonstrate abnormalities of the ACC in ASD as compared to typically developing control patients. However,
little is known regarding the cellular basis of these functional deficits in ASD. Pyramidal neurons in the ACC are excitatory
glutamatergic neurons and key cellular mediators of the neural output of the ACC. This study was designed to investigate
the potential role of ACC pyramidal neurons in ASD brain pathology.
Methods: Postmortem ACC tissue from carefully matched ASD and typically developing control donors was obtained
from two national brain collections. Pyramidal neurons and surrounding astrocytes were separately collected from layer
III of the ACC by laser capture microdissection. Isolated RNA was subjected to reverse transcription and endpoint PCR
to determine gene expression levels for 16 synaptic genes relevant to glutamatergic neurotransmission. Cells were also
collected from the prefrontal cortex (Brodmann area 10) to examine those genes demonstrating differences in expression
in the ACC comparing typically developing and ASD donors.
Results: The level of NTRK2 expression was robustly and significantly lower in pyramidal neurons from ASD donors as
compared to typically developing donors. Levels of expression of GRIN1, GRM8, SLC1A1, and GRIP1 were modestly lower
in pyramidal neurons from ASD donors, but statistical significance for these latter genes did not survive correction for
multiple comparisons. No significant expression differences of any genes were found in astrocytes laser captured from
the same neocortical area. In addition, expression levels of NTRK2 and other synaptic genes were normal in pyramidal
neurons laser captured from the prefrontal cortex.
Conclusions: These studies demonstrate a unique pathology of neocortical pyramidal neurons of the ACC in ASD.
NTRK2 encodes the tropomyosin receptor kinase B (TrkB), transmission through which neurotrophic factors modify
differentiation, plasticity, and synaptic transmission. Reduced pyramidal neuron NTRK2 expression in the ACC could
thereby contribute to abnormal neuronal activity and disrupt social behavior mediated by this brain region.
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Autism spectrum disorder (ASD) is a neurodevelopmental
disorder that includes repetitive behaviors and impair-
ments in social communication and interaction [1]. In re-
cent years, ASD and disorders associated with autism
behaviors have largely been attributed to genetic etiology
[2]. However, it is likely that the heterogeneity of ASD re-
sults from a complex interplay of inherited genetics and
developmental influences that result in abnormal intercel-
lular communication in the brain. It is anticipated that
areas of the brain that modulate the behaviors that are dis-
rupted in ASD are particularly vulnerable to the pathobio-
logical processes of ASD and likely include disrupted
connectivity between discrete areas of the brain that
modulate behaviors that are abnormal from infancy.
The anterior cingulate cortex (ACC) is the cortical gyrus
surrounding the corpus callosum in the human brain.
Anatomically, the ACC shares a complex relationship with
several other brain regions including the amygdala, hypo-
thalamus, parietal, and other regions of the prefrontal cor-
tex (as reviewed by Bush et al., 2000 [3]). The ACC has
consistently displayed abnormalities in ASD as revealed
through imaging and neuroanatomical studies. Functional
MRI studies have demonstrated differences when compar-
ing typically developed controls with ASD patients, in-
cluding reduced activation of the anterior cingulate cortex
(ACC) during true/false judgments [4], novelty detection
[5], response inhibition [6,7], attention tasks [8], and in-
creased activation of the ACC during social target detec-
tion and nonsocial rewarding [9]. Other studies using
SPECT [10], EEG [11-14], PET [15-18], and fractional an-
isotropy [19,20] have also demonstrated abnormalities in
the cingulate cortex in ASD.
The few postmortem studies that have focused on the
ACC have identified molecular and anatomical differences
between ASD and typically developing control brain tis-
sue. Stereology studies using the neocortex of the ACC in-
dicated that neurons were smaller and demonstrated
increased cell packing density [21]. Reductions in both
mRNA and protein levels of the axonal guidance proteins
plexinA4 and roundabout 2 were identified in tissue ho-
mogenates from the ACC from ASD donors [22], as well
as alterations in serotonin- [23] and GABA- [24,25] re-
lated genes. Interestingly, increased gene expression in the
transcriptional control factor, Sp1, was found in postmor-
tem ACC from ASD donors [26], which could have wide-
spread implications and contribute to the complexity of
ASD. Collectively, these studies demonstrate that path-
ology in the ACC exists in autism. However, little is
known regarding the cellular basis of ACC pathology.
Pyramidal neurons in layer III of the neocortex are key
cellular mediators of the neural output of the ACC.
These pyramidal cells are excitatory glutamatergic neu-
rons that have a complex synaptic relationship withmany other cell types in other neocortical layers of the
ACC, including inhibitory neurons, glia, and long-range
projecting glutamate neurons of layer V. The current
study was undertaken to investigate the molecular path-
ology of pyramidal cells in layer III of the ACC from ASD
donors. The levels of expression of several glutamate-
related genes were measured specifically in pyramidal neu-
rons captured by laser microdissection from layer III of
the ACC from postmortem brain tissue from ASD donor
and typically developing control subject brain tissue. The
glutamate-related genes chosen for study were those asso-
ciated with ASD identified in gene association, laboratory
animal, and/or postmortem pathology studies [27-32]
and/or because of their strong association with gluta-
matergic neurotransmission. Additionally, two neuro-
trophic factor genes (brain-derived neurotrophic factor
(BDNF) and NTRK2) were studied because of the link be-
tween glutamatergic transmission and BDNF signaling
[33] and the association of BDNF and NTRK2 pathology
in ASD [34]. The findings of this study demonstrate that
ACC in ASD is associated with abnormal levels of expres-
sion of several genes related to glutamate neurotransmis-
sion, with the most striking finding being a robust
reduction of NTRK2 gene expression.
Methods
Brain tissue
Brain tissues from ASD and typically developing control
donors were provided by the National Institutes for Child
Health and Development (NICHD) Brain and Tissue
Bank (Baltimore, MD) and the Autism Tissue Program
(Belmont, MA). These brain banks were responsible for
obtaining subject consent and the unidentifiable coding
of subject information. This study was reviewed and ap-
proved for exemption by the Institutional Review Board
of East Tennessee State University under the Department
of Heath and Human Services exemption 45 CFR
46.101(b) relating to the use of publicly available un-
identifiable pathology specimens. In total, brain tissue
from 12 typically developing control donors and 12
ASD donors were used for the different experiments
(see Table 1). Comorbidities and causes of death were
not included in the table in order to protect donor iden-
tities. Typically developing control donors died by
drowning (3 donors), heart condition (3 donors), trauma
(3 donors), asphyxia (1 donor), pneumonia (1 donor), and
unknown cause (1 donor). It should be mentioned that
one control donor was diagnosed with depressive disor-
ders and died by suicide. The ASD donors died by trauma
(3 donors), asphyxia (3 donors), acute respiratory distress
syndrome (1 donor), cardiopulmonary arrest (1 donor),
cancer (1 donor), diabetic ketoacidosis (1 donor), bowel
obstruction (1 donor), and cardiac arrhythmia (1 donor).
One ASD donor could not be medically confirmed as
Table 1 Subject demographic information
Pair ID Age Gender RINa PMI (hours)b Toxicology Assays Tissue
Control donors
1 AN14757 24 M 7.8 21.33 No drugs reported LCMc, qPCRd BA24, BA10
2 AN07176 21 M 8 29.91 No drugs reported LCM, qPCR BA24, BA10
3 AN07444 17 M 7.5 30.75 Sertraline LCM, qPCR BA24
4 5408 6 M 7 16 No drugs reported LCM, qPCR BA24, BA10
5 4848 16 M 7.6 15 No drugs reported LCM, qPCR BA24, BA10
6 5342 22 M 8.1 14 No drugs reported LCM, qPCR BA24, BA10
7 5079 33 M 7.3 16 Ethanol LCM, qPCR BA24, BA10
8 M3231M 37 M 7.4 24 No drugs reported LCM, qPCR BA24, BA10
9 4590 20 M 7.6 19 No drugs reported LCM, qPCR BA10
Mean ± SEM (BA24 donors) 22.0±3.4 7.59±0.13 20.9±2.4
Mean ± SEM (BA10 donors) 22.4±3.4 7.60±0.13 19.4±1.9
ASD donors
1 AN04166 24 M 8.1 18.51 No drugs reported LCM, qPCR BA24, BA10
2 AN03935 20 M 8.6 28 No drugs reported LCM, qPCR BA24, BA10
3 AN02987 15 M 6.5 30.83 No drugs reported LCM, qPCR BA24
4 5144 7 M 8.0 3 No drugs reported LCM, qPCR BA24, BA10
5 5302 16 M 6.6 20 Risperidone, fluvoxamine,
clonidine, insulin
LCM, qPCR BA24, BA10
6 5176 22 M 7.1 18 Risperidone LCM, qPCR BA24, BA10
7 5297 33 M 7.1 50 Quetiapine, fluoxetine,
valproate, ziprasidone
LCM, qPCR BA24, BA10
8 5027 37 M 7.7 26 Risperidone, fluvoxamine LCM, qPCR BA24, BA10
9 4999 20 M 7.0 14 No drugs reported LCM, qPCR BA10
Mean ± SEM (BA24 donors) 21.6±3.4 7.46±0.27 24.3±4.8
Mean ± SEM (BA10 donors) 22.2±3.3 7.53±0.24 23.4±5.4
P valuee (BA 24) 0.94 0.68 0.53
P valuee (BA10) 0.98 0.79 0.60
aRNA integrity number (index of RNA quality); bpostmortem interval; cendpoint PCR analysis of reversed transcribed RNA isolated from cells collected by laser capture
microdissection; dquantitative polymerase chain reaction of reverse transcribed RNA isolated from punch-dissected tissues; eresults of a two-tailed independent t-test
comparing control and ASD groups. BA24, Brodmann area 24; BA10, Brodmann area 10; LCM, laser capture microdissection.
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ure episode but did not have a medical diagnosis of seiz-
ure disorder. The samples were closely matched by
gender and age. For each control and ASD pair, the
donor tissue came from the same brain bank and was not
anatomically characterized by subregions of Brodmann
area 24 (BA24) or Brodmann area 10 (BA10). Additionally,
we analyzed RNA integrity values (RIN, index of RNA
quality) in matched pairs of donors prior to experimenta-
tion to be sure these were closely matched for the paired
analyses [35].
Tissue preparation
Blocks of tissue containing ACC, specifically BA24, and
prefrontal cortex BA10 were received and stored at −80°C.
All brain tissues were obtained from the left hemisphereexcept AN03935. Tissue homogenates used for quantita-
tive PCR were obtained using a 3.5-mm trephine to
punch-dissect a 50-μm-thick section of gray matter from
the anterior cingulate that contained all six neocortical
layers. A cryostat microtome was used to section tissue
blocks for laser capture microdissection (LCM). Tissue
from the cortex was sectioned at −20°C and 10-μm-thick
sections were mounted slides that were immediately
placed in a chilled microslide box on ice. Between each
tissue block, all physical elements of cryosectioning were
thoroughly cleaned with 100% ethanol to avoid any cross
contamination. Sectioned tissue was desiccated at room
temperature for 5 min and stored at −80°C until use. Tis-
sues from the same control/ASD donor pair were sec-
tioned and processed on the same day to ensure that
storage time after sectioning was identical.
Chandley et al. Molecular Autism  (2015) 6:28 Page 4 of 12Laser capture microdissection
Neurons were visualized by staining frozen tissue sec-
tions with the Histogene staining kit (Life Technologies;
Grand Island, NY, USA) according to the manufacturer’s
instructions (Figure 1C). In short, the protocol used a cre-
syl violet stain on an ethanol-fixed slide followed by a
series of dehydration steps. Stained slides were placed in a
vacuum chamber until ready for LCM. Astrocytes were
identified using a modified glial fibrillary acidic protein
(GFAP) rapid immunohistochemistry protocol as previ-
ously described (Figure 1E) [36,37]. Briefly, tissue-mounted
slides were fixed in acetone (5 min), blocked in horse
serum (10 min), incubated with GFAP antibody (10 min;
ThermoFisher; Pittsburgh, PA, USA), anti-mouse antibody
(5 min; Vectastain; Burlingame, CA, USA), and avidin-
biotinylated horseradish peroxidase (5 min; Vectastain;
Burlingame, CA, USA). GFAP immunoreactivity was vi-
sualized by exposure to diaminobenzidine (DAB) (Sigma;
St. Louis, MO, USA) with ammonium nickel sulfate
(ANS) (Sigma; St. Louis, MO, USA) for 5 min, then ex-
posed to DAB/ANS with 0.1% H2O2 for an additional 5
min. Afterwards, the slide was ethanol dehydrated then
placed in xylene for 5 min. The slide was kept in a vac-
uum chamber for 10 min prior to LCM.Figure 1 Laser capture microdissection of pyramidal neurons and
astrocytes. Shown in (A) is the absence of laser captured nissl-
stained pyramidal neurons from cortical layer 3 in BA24 gray matter
tissue following capture (20× magnification). (B) shows those cells
adhered to the polymer cap (20× magnification). (C) and (D) illus-
trate the before (C) and after (D) capture images for nissl-stained
BA24 pyramidal neurons (40× magnification). (E) and (F) show the
same laser capture process for GFAP immunostained astrocytes in
BA24 gray matter (60× magnification).LCM was performed using an ArcturusXT (Life Tech-
nologies; Grand Island, NY, USA) instrument. Neurons
were extracted onto CapSure macrocaps (Life Technolo-
gies; Grand Island, NY, USA) using a 25-μm spot size that
is first placed onto the cap by infrared (IR) laser spotting
and then cut by an ultraviolet (UV) laser. Neurons were
morphologically identified in layer III of the neocortex at
40× magnification. Astrocytes were captured using an
Arcturus Veritas (Life Technologies; Grand Island, NY,
USA) instrument. Astrocytes were morphologically identi-
fied at 60× magnification and placed onto caps by IR laser
using a 10-μm spot size. Cells were removed from cap
using lysis buffer incubation at 42°C.
RNA preparation and reverse transcriptase
Total RNA was extracted from tissue homogenates using
the Maxwell simplyRNA LEV kit (Promega; Madison, WI,
USA) and from laser captured cells using the RNAqueous
Micro kit with DNase treatment (Life Technologies;
Grand Island, NY, USA). RNA quality was assessed by
measuring RIN values obtained using the Agilent 2100
Bioanalyzer (Agilent Technologies; Santa Clara, CA,
USA). RNA samples were reverse transcribed into cDNA
using the Superscript III kit (Life Technologies; Grand
Island, NY, USA) that contained oligodT and random
hexamer primers.
Quantitative PCR
Gene-specific primers were either designed using Mfold
web server software [38] and primer quest design software
(IDT; Coralville, IA, USA) to generate approximately 100
base pair amplicons to span exon junctions or were pur-
chased from a vendor (Qiagen; Valencia, CA, USA). Gene
primer sequences are shown in Additional file 1. To quan-
tify transcripts, endpoint PCR was used for RNA isolated
from laser captured cells and real-time quantitative PCR
(qPCR) was used for RNA isolated from tissue homoge-
nates as previously described [36,39]. For endpoint PCR
reactions (BDNF, GRIN2D, GRIN2B, and GRM8) that
were initially problematic using 5Prime Hot Master Mix
taq polymerase (5Prime; Gaithersburg, MD, USA), a
modified polymerase from Qiagen (Valencia, CA, USA)
was employed using the same reaction parameters.
Statistical analysis
Calculations for qPCR data involved converting cycle
threshold (CT) values to fold-change between control and
autism donors using the 2−ΔΔCT method by Livak and
Schmittgen [40]. Endpoint PCR data was computed as
relative values generated from the ratios of amounts of
target gene expression to the average of two reference
gene expressions. Afterwards, both data from qPCR and
endpoint PCR were analyzed by the paired Student t-test.
Statistical results are reported before and after Holm’s
Table 2 Results of Holm-Bonferroni sequential correction
of multiple paired Student’s t-tests of gene expression
data from BA24 neurons
Gene (protein) P value from
paired t-test
P’ from correctiona Significance?
RNA18S1/GAPDH 0.3774 1.000 No
GRIN1 (NR1) 0.0533 0.583 No
GRIN2A (NR2A) 0.9051 1.000 No
GRIN2B (NR2B) 0.1160 1.000 No
GRIN2C (NR2C) 0.9924 1.000 No
GRIN2D (NR2D) 0.1146 1.000 No
GRIA1 (GluR-1) 0.2424 1.000 No
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sons as noted in the results below. Pearson’s correlation
was used to determine possible effects of postmortem var-
iables (age, RIN, and postmortem interval time (PMI)) on
the expression of each gene. Given the number of correl-
ation tests, a P < 0.01 was chosen a priori to indicate stat-
istical significance in order to reduce type I errors.
Multivariate analysis of variance (MANOVA) for unpaired
data was performed using IBM SPSS Statistics (version
21.0.0.0, IBM, New York, NY, USA) and graphed using
Prism (version 5.0b, GraphPad Software, La Jolla, CA,
USA). All other analyses were performed and graphed
using Prism.GRIK2 (GRIK2, GluK2) 0.3793 1.000 No
GRM5 (mGluR5) 0.1061 1.000 No
GRM8 (mGluR8) 0.0340 0.408 No
SLC1A1 (EAAT3) 0.0235 0.312 No
SLC17A7 (VGlut1) 0.5034 1.000 No
GRIP1 (GRIP1) 0.0064 0.090 No
BDNF (BDNF) 0.4846 1.000 No
NTRK2 (NTRK2,TrkB) 0.0006 0.009 Yes
aHolm-Bonferroni corrected P value.Results
Glutamate-related gene expression
The levels of expression of seven ionotropic glutamate
receptor subunit genes (GRIN1, GRIN2A, GRIN2B,
GRIN2C, GRIN2D, GRIK2, GRIA1) and two metabotro-
pic glutamate receptor genes (GRM5, GRM8) were mea-
sured in BA24 pyramidal neurons and surrounding
astrocytes from ASD and age-matched control donors.
GRM8 expression was not detectable in astrocytes.
Levels of GRM8 expression were modestly lower in pyr-
amidal neurons from ASD donors compared to matched
control donors (t = 2.89; P = 0.034), but statistical sig-
nificance was lost when the P value was corrected for
the number of matched pair comparisons of gene ex-
pressions in neurons (Table 2). Likewise, GRIN1 expres-
sion levels trended towards being lower in ASD as
compared to control donors (P = 0.053), but this differ-
ence was lost upon correction for the number of com-
parisons (Table 2). No other differences in the levels of
expression of any glutamate receptor gene were ob-
served in either pyramidal neurons or astrocytes com-
paring ASD to control donors (Figure 2).
Additional genes associated with glutamatergic neuro-
transmission were interrogated in BA24 pyramidal neu-
rons and astrocytes, including glutamate transporter
genes, SLC1A1, SLC1A2, SLC1A3, SLC17A7, and the glu-
tamate receptor interacting gene, GRIP1. Of these genes,
the expression of astrocyte-associated transporter genes
SLC1A2 and SLC1A3 was not measured in neurons and
the neuronal glutamate transporter gene SLC1A1 was
not measured in astrocytes. Levels of SLC1A1 (t = 2.88;
P = 0.024) and GRIP1 (t = 3.84; P =0.006) gene expres-
sion were lower in pyramidal neurons captured from
ASD donors as compared to matched control donors
(Figure 3). However, statistical significance was lost
when P values were corrected for the number of
matched pair comparisons (Table 2). No significant dif-
ferences in the levels of expression of any of the
glutamate-related genes, SLC1A2, SLC17A7, and GRIP1,were observed in astrocytes comparing ASD to matched
control donors (Figure 3).
BDNF/NTRK2
Levels of expression for the neurotrophic factor gene
BDNF and its receptor gene NTRK2 were measured in
pyramidal neurons and astrocytes from BA24 (Figure 4).
BDNF expression in both neurons and astrocytes was
similar comparing ASD to matched control donors. How-
ever, NTRK2 expression levels were robustly lower in pyr-
amidal neurons (t = 5.87; P = 0.0006), but not astrocytes,
from ASD donors as compared to control donors. The dif-
ference in NTRK2 expression levels between ASD and
control donors remained statistically significant after cor-
rection for the number of matched comparisons (Table 2).
Expression of selected genes in BA10
The expression levels of five genes were studied in BA10
pyramidal neurons from ASD and control donors.
Chosen for study were those genes analyzed in BA24
pyramidal neurons that demonstrated either no differ-
ence (GRM5), marginal or modest differences (GRIN1,
SLC1A1), or highly significant differences (NTRK2) com-
paring ASD to control donors as noted above. In this set
of experiments, BA10 tissue from one age-matched pairs
of donors used in the BA24 studies above was not avail-
able; BA10 tissue from one different age-matched pair of
donors was substituted as noted in Table 1. The expres-
sion levels of each of these five genes in laser captured
Figure 2 Levels of expression of ionotropic glutamate receptor subunits and metabotropic glutamate receptors (A-I). Expression of glutamate
receptors and receptor subunits was measured in laser captured BA24 pyramidal neurons and separately in surrounding astrocytes of typically
developing control donors (open symbols) and ASD donors (closed symbols). Gene expression levels are normalized to the averaged levels of
expression of references genes (GAPDH and RNA18S1). Mean values are noted by horizontal lines, and statistical significance (uncorrected for the
number of comparisons) is noted above the data points. See Table 2 for statistical results following correction for the number of comparisons.
Chandley et al. Molecular Autism  (2015) 6:28 Page 6 of 12pyramidal neurons from BA10 were similar in ASD and
matched controls (Figure 5; GRIN1 t = 0.74, P = 0.49;
GRM5 t = 0.90, P = 0.40; SLC1A1 t = 0.26, P = 0.80;
NTRK2 t = 0.03, P = 0.97).
Demographic variables, reference genes, and tissue factors
There were no statistical differences between ASD and
matched control donors of BA24 tissue regarding age,
RIN or PMI values (Table 1). Likewise, there were no
differences in these variables comparing the groups of
donors of BA10 tissue (Table 1). There were no signifi-
cant correlations between age or PMI and any of the 15
gene expressions measured in BA24 pyramidal neurons
(Additional file 2). There was a significant correlation
between levels of GRIN2C expression and RIN values,
but there were no other correlations between RIN and
the levels of any mRNA that was studied in BA24 pyr-
amidal neurons. In BA24 astrocytes, age correlated sig-
nificantly with NTRK2 gene expression levels (P = 0.002)
but not with levels of any other gene (Additional file 3).
RIN did not significantly correlate with expression levels
of any gene in BA24 astrocytes, while PMI correlatedwith only SLC17A7 gene expression in BA24 astrocytes
(Additional file 3). In BA10 pyramidal neurons, there
were no significant correlations between age, RIN, or
PMI and the levels of expression of any of the target or
reference genes (Additional file 4).
Reference genes were carefully chosen as those that
were stable in their expression levels across the two
groups of donors. The ratios of levels of expression of
RNA18S1 and GAPDH were not significantly different in
laser-captured BA24 neurons (t = 1.00, P = 0.35), BA24
astrocytes (t = 0.93, P = 0.38), or BA10 neurons (t = 1.82,
P = 0.11) comparing ASD and matched control donors
(see Additional file 5).
It should be noted that we wished to screen multiple
brain regions for these gene expression changes to deter-
mine the extent to which they occurred in the brain. Be-
cause LCM is time-intensive and expensive, we attempted
to measure SLC1A1, GRIP1, and NTRK2 expression in
RNA isolated from homogenates of ACC. However, we
were unable to detect any differences in expression of these
genes in RNA isolates from homogenates of ACC, using
tissues collected from seven of the eight ASD - control
Figure 3 Levels of expression of glutamate transporter genes and a glutamate receptor-interacting gene (A-E). Gene expression was measured in
laser captured BA24 pyramidal neurons and separately in surrounding astrocytes of typically developing control donors (open symbols) and ASD
donors (closed symbols). Gene expression levels are normalized to the averaged levels of expression of references genes (GAPDH and RNA18S1).
Mean values are noted by horizontal lines, and statistical significance (uncorrected for the number of comparisons) is noted above the data points. See
Table 2 for statistical results following correction for the number of comparisons.
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(Figure 6). No significant difference was found for the
ratios of expression of the reference genes GAPDH and
TATA from the homogenate punch samples when com-
paring ASD and control donors (Additional file 6; t = 0.19,
P = 0.86).
Four of the ASD donors had been prescribed psycho-
therapeutic medications, with three of the four receiving
selective serotonin retake inhibitors (SSRI) antidepres-
sants and four of the four receiving antipsychotic drugs
(see Table 1). Considering that effects of psychothera-
peutic drugs might contribute to observed differences in
gene expression in BA24 neurons as shown above, a
comparison was made of antidepressant/antipsychotic-
exposed ASD donors to ASD donors not exposed toFigure 4 Levels of expression of BDNF (A) and its receptor gene NTRK2 (B). G
and separately in surrounding astrocytes of typically developing control dono
levels are normalized to the averaged levels of expression of references gene
statistical significance (uncorrected for the number of comparisons) is noted ab
the number of comparisons. BDNF, brain-derived neurotrophic factor.these drugs. Albeit the sample sizes of these two groups are
small and that these two subgroups were not matched for
age and other demographic variables, there were no signifi-
cant difference in levels of GRM8 (unpaired t-test; t = 0.17,
P = 0.87), GRIP1 (0.01, P = 0.99), SLC1A1 (t = 0.28, P =
0.79), and NTRK2 (t = 0.59, P = 0.57) comparing anti-
depressant/antipsychotic-exposed ASD donors to ASD do-
nors without these drugs.
Statistical considerations
Data from the matched control and ASD cases were an-
alyzed using a paired t-test. Paired analyses were chosen
because ASD and control donors were matched prior to
the initiation of the analyses of gene expression levels
based on several factors including, gender, age, and RNAene expression was measured in laser captured BA24 pyramidal neurons
rs (open symbols) and ASD donors (closed symbols). Gene expression
s (GAPDH and RNA18S1). Mean values are noted by horizontal lines, and
ove the data points. See Table 2 for statistical results following correction for
Figure 5 Levels of expression of GRM5, GRIN1, SLC1A1, and NTRK2 in
pyramidal neurons of BA10. Gene expression was measured in laser
captured BA10 pyramidal neurons from typically developing control
donors (open symbols) and ASD donors (closed symbols). Gene expression
levels are normalized to the averaged levels of expression of references
genes (GAPDH and RNA18S1). Mean values are noted by horizontal
lines. No statistically significant differences were observed.
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important for matching since each would be expected to
impact measurements of gene expression levels. In
addition, as noted in Methods, tissues from matched
pairs of donors were processed on the same day so that
RNA storage times were matched. Later, reverse tran-
scription of RNA was performed on the same day for
matched donor pairs, and PCR amplifications were per-
formed simultaneously and run on the same plate. Given
the meticulous care in the pairing of tissue donors and
experiments that were performed on these tissues, we
feel most confident with the results of the paired ana-
lyses of the resulting data. Alternative unpaired analyses
could be used with the argument that all samples are
taken from two separate groups of unrelated donors. To
consider this, we subjected gene expression data fromFigure 6 Ratio of reference gene expression levels. Gene expression
was measured for GAPDH and RNA18S1 in typically developing control
donors (open symbols) and ASD donors (closed symbols). The ratio of
gene expression between the two reference genes was compared for
control and ASD subjects for BA24 neurons and astrocytes and BA10
neurons to ensure that the reference genes had stable expression levels
between the groups. No statistically significant differences were observed.BA24 pyramidal neurons to MANOVA. The results of
the MANOVA demonstrated a significant group effect
(F = 563.3(7,1); P = 0.03), with significantly lower expres-
sion levels of NTRK2 (P = 0.002) in the ASD group as
compared to the control group, similar to that observed
in the paired analysis above. In addition, expression
levels of GRIN1 (P = 0.009) and GRM8 (P = 0.02) were
lower in ASD as compared to control donors.
Discussion
This study examined the expression of genes involved in
glutamatergic neurotransmission in ASD. We found a
robust reduction in expression of a neurotrophin recep-
tor gene (NTRK2) in pyramidal neurons dissected by
LCM from ACC tissue of donors with ASD when com-
pared to typically developing controls. In addition, there
were trends towards low levels of expression of genes
encoding a metabotropic glutamate receptor (GRM8), an
ionotropic glutamate receptor subunit (GRIN1), a glu-
tamate transporter (SLC1A1), and a glutamate receptor
anchoring protein (GRIP1). This is the first study to use
LCM to isolate a specific cell population to examine the
molecular pathology of ASD. The use of LCM to capture
distinct cell populations provided cellular resolution to
the assessment of pathology and permitted identification
of gene expression changes that we were unable to detect
using homogenates of the same brain region in the same
subjects. The difference in the results of LCM of single
cell populations versus homogenates of tissues is likely the
result of overlapping gene expression in other unaffected
cell types that in essence dilute cell-specific gene expres-
sion changes, as has been demonstrated in research on
Alzheimer’s disease [43,44]. The gene expression deficits
identified in the present study were restricted to ACC pyr-
amidal neurons and not found in surrounding astrocytes
in the same brain region, nor in pyramidal neurons in
BA10 of the prefrontal cortex, suggesting the presence of
a cell- and region-specific pathology in ASD.
A striking finding of this study was the decreased ex-
pression of the growth factor receptor gene NTRK2 in
ACC pyramidal neurons from ASD donors. This gene en-
codes the high-affinity tyrosine kinase B receptor, TrkB,
the primary ligand for which is BDNF, but neurotrophin-3
(NT-3) and neurotrophin-4/5 (NT-4/5) also can signal
through the TrkB receptor [45,46]. TrkB signaling is crit-
ical to cell function, with ligand-activated TrkB engaging
several intracellular signaling pathways including mitogen-
activated protein kinase (MAPK), phosphoinositide 3-
kinase (PI3), and extracellular-signal-regulated kinase
(ERK) that are important in neurotransmission, plasti-
city, and differentiation [47]. Other evidence of abnor-
mal BDNF/TrkB signaling in ASD includes several
reports of elevated peripheral and central BDNF levels
in ASD [34,48-51]. Given the multitude of effectors of
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could have severe consequences on brain development
and function. NTRK2-deficient mice die soon after birth
[52,53], but mice with a conditional loss of NTRK2 ex-
pression exhibit a wide variation in behavior ranging from
social deficits to antisocial behavior (as reviewed by Lind-
holm and Castrén, 2014 [54]). It is noteworthy that the
BTBR T+tf/J mouse model for ASD exhibits reduced TrkB
protein expression [55]. Defective TrkB signaling has been
shown in Angelman [56] and Fragile X [57] mouse
models, both of which are syndromes with a high inci-
dence of autistic features. The present study provides fur-
ther support for a role of deficient BDNF/TrkB signaling
in ASD, specifically implicating reduced TrkB signaling in
ACC pyramidal neurons.
A genetic association between polymorphisms of NTRK2
and ASD has been identified [34]. The most strongly asso-
ciated polymorphisms in ASD were found in the intron-
spanning regions of NTRK2 [30]. It seems unlikely that a
polymorphism in NTRK2 would account for the reduction
in NTRK2 expression in pyramidal cells observed in the
present study since one would expect the polymorphic
NTRK2 to similarly affect NTRK2 expression in astrocytes
and pyramidal neurons in other brain regions. Of the cells
studied, we found the reduction of NTRK2 expression
only in ACC pyramidal neurons.
Cells used for this study were dissected from neocor-
tical layer III of the ACC where both changes in cell size
and packing density have been demonstrated previously
[21]. An elevated number of neurons detected in layer
VI of the ASD ACC have been interpreted as a possible
incomplete migration of neurons during development
[21]. Mini-column disturbances, that is, reduced column
width and increased column number in ASD, have been
shown in the ACC with pyramidal neurons demonstrating
misalignment [58]. Stoner et al. [59] recently reported ab-
normal columnar architecture in several cortical regions
involving all six cortical layers, based on abnormal gene
expressions and areas referred to as “patches” [59] with
low gene expression levels. The ACC was not investigated
in this later study. In addition, an increase in spine density
of pyramidal neurons in frontal, parietal, and temporal
lobes has been reported for ASD [60], although spine
density specifically in the ACC has not been studied to
date. Interestingly, BDNF/TrkB signaling plays a promin-
ent role in synaptogenesis and synaptic remodeling of ex-
citatory neurons during development [61,62]. Hence, low
levels of NTRK2 expression in glutamatergic pyramidal
neurons in ASD observed in the present study may be
etiologically linked to abnormalities in cortical columnar
architecture in ASD previously reported.
Abnormalities in neurotransmitter signaling networks
are likely to be a core component of the cellular neuro-
biology of ASD. Gene expression changes in synapse-related genes have been demonstrated in disorders that
have autistic features such as Angelman syndrome and
Fragile X syndrome (as reviewed by Ebert and Greenberg,
2013 [63]). We chose to interrogate potential expression
changes in several genes associated with excitatory amino
acid cell signaling in autism. Four of these genes, SLC1A1,
GRIP1, GRIN1, and GRM8, demonstrated trends towards
reduced expression in ACC pyramidal neurons in ASD.
SLC1A1 is responsible for glutamate uptake from the syn-
apse by pyramidal neurons while GRIP1 anchors AMPA
receptors to the cell membrane. GRIN1 is the mandatory
subunit of the N-methyl-D-aspartate (NMDA) receptor
and GRM8 inhibits the adenylyl cyclase/cAMP pathway
and decreases the likelihood of cell death associated with
excess NMDA signaling [64]. The decreased expression of
GRM8 receptor in ASD, if accompanied by reduced
GRM8 receptor, could leave pyramidal cells susceptible to
neurotoxic effects of elevated glutamate signaling through
the NMDA receptor. This neurotoxic effect could be amp-
lified further if reduced SLC1A1 expression observed in
ASD results in less glutamate transporter activity at the
glutamatergic synapse, thereby further increasing glutam-
ate activation of NMDA receptors on these pyramidal
neurons. Reduced GRIP1 expression, as we observed in
ASD, could be a compensatory mechanism to override ex-
cess NMDA receptor activation by glutamate. Whatever
the exact sequence or consequence, abnormal expression
levels of these genes imply that excitatory output from the
ACC via pyramidal neurons is disrupted in ASD. Because
multiple cell types express GRIP1 and NTRK2, it cannot
be dismissed that these glutamatergic-related gene ex-
pression decreases are only found in excitatory cells.
While we did not find GRIP1 or excitatory transporter
changes (SLC1A2 and SLC1A3) in the glia cells studied
herein, altered expression of these genes could occur in
inhibitory neurons of the ACC, which were not studied.
Nevertheless, any disruption of glutamate transmission
and function implicates a compromise in the delicate bal-
ance of inhibitory and excitatory neuronal activity of the
ACC. Future studies need to include a more detailed exam-
ination of gene expression in other cell types of the ACC.
Limitations
There were several limitations in the current study that
should be taken into consideration. First, like many
studies of ASD relying on postmortem brain tissue, the
number of donors available was limited and reduced the
power of the study. It should be noted that all donors
that had a history of seizure disorder were excluded
from the study to reduce experimental variability. It is
worth noting that our laboratory has observed that the
study of gene expression in distinct cell populations cap-
tured by LCM results in reduced variability of data, per-
mitting the use of smaller sample sizes to obtain statistical
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there were not enough brain donors to permit us to exam-
ine the gene expressions in subgroups of donors based on
clinical presentation. Changes in gene expression do not
always correlate with changes in the expression of the cog-
nate protein, and often a change in gene expression is not
temporally correlated with changes in the cognate pro-
teins. Hence, whether reduced NTRK2 expression in ASD
pyramidal neurons results in lower TrkB protein in these
cells is not currently known. Nevertheless, altered levels of
NTRK2 expression in ASD is highly suggestive of per-
turbed TrkB signaling in ASD. ASD donors used in the
present study were exposed to psychotherapeutic drugs
that could alter gene expression, particularly SSRI and ris-
peridol, an atypical antipsychotic. But, repeated adminis-
tration of the antidepressants tranylcypromine, sertraline,
or desipramine to rats increases NTRK2 expression [65].
Hence, reduced NTRK2 expression in the present study is
unlikely to reflect previous antidepressant drug therapy.
Repeated treatment of rats with risperidol produced no
change in TrkB immunoreactivity in the brain [66], again
suggesting that psychotherapeutic drug exposure is not a
likely mediator of reduced NTRK2 expression in ASD in
the present study. Findings herein demonstrate no obvi-
ous effect of psychotherapeutic drug exposure on NTRK2
(or GRIN1, GRM8, GRIP1, SLC1A1) expression. Finally,
tissue-related physical factors were considered as possible
sources of variance in these experiments. However, there
were no significant differences between ASD and control
donor samples when comparing age, RNA quality (RIN),
and postmortem intervals (Table 1).
Conclusions
Multiple gene abnormalities are significantly associated
with ASD [67]. It therefore seems likely that multiple
etiologies exist that can result in ASD. Brain pathology
is downstream to gene polymorphisms and etiologies
and more proximal to the pathophysiology underlying
the abnormal behaviors. Hence, the neuropathology of
ASD may be more limited in terms of variability than
the genotypes that can contribute to it, that is, different
etiologies may result in a similar structural/neurochem-
ical abnormalities that disrupt function to produce a
specific set of behavioral abnormalities. The present
study was designed to examine possible disruption of a
key neuronal unit, the glutamatergic pyramidal neuron,
of the ACC in ASD. The data presented here reveals
strong evidence of disrupted neurochemistry of ACC
pyramidal neurons, specifically involving glutamatergic
neurotransmission and neurotrophic factor (BDNF) sig-
naling through the TrkB receptor. It is tempting to
speculate that abnormalities in ACC as revealed in im-
aging studies of ASD patients [4-7,9,11-16,68] and path-
ology research using postmortem brain tissues [21-25]are at least partially the result of deficits in pyramidal
neuronal function in the ACC as revealed in the present
study. Pyramidal neurons in layer III of the ACC synapse
with other cortical neurons including inhibitory neurons
and long-range pyramidal motor neurons in layer V and
the present findings suggest that neural communication
with these other brain areas or pathways is altered in
ASD. Interestingly, pyramidal neurons take years to
reach maturity, possibly well into adolescence [69], indi-
cating that normal neural development of this cell type
may be especially vulnerable to deleterious environmen-
tal influences occurring early in life.
Additional files
Additional file 1: Primer information.
Additional file 2: Pearson’s correlation analyses for possible
relationships between gene expression levels in BA24 neurons and
age, RNA quality (RIN), and postmortem interval (PMI).
Additional file 3: Pearson’s correlation analyses for possible
relationships between gene expression levels in BA24 astrocytes
and age, RNA quality (RIN), and postmortem interval (PMI).
Additional file 4: Pearson’s correlation analyses for possible
relationships between gene expression levels in BA10 neurons and
age, RNA quality (RIN), and postmortem interval (PMI).
Additional file 5: Ratio of reference gene expression levels. Gene
expression was measured for GAPDH and RNA18S1 in typically developing
control donors (open symbols) and ASD donors (closed symbols). The ratio
of gene expression between the two reference genes was compared for
control and ASD subjects for BA24 neurons and astrocytes and BA10
neurons to ensure that the reference genes had stable expression levels
between the groups. No statistically significant differences were observed.
Additional file 6: Ratio of reference gene expression levels for
qPCR. Gene expression was measured for GAPDH and TATA in typically
developing control donors (open symbols) and ASD donors (closed
symbols). The ratio of gene expression between the two reference genes
were compared for control and ASD subjects for BA24 punch-dissected
gray matter tissue samples to ensure that the reference genes had stable
expression levels between the groups. No statistically significant difference
was observed.
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